IFNA2 and melanoma: After their discovery more than 50 years ago, the FDA approved the first recombinant IFNa2b (Intron A®)-based drug in 1986 (almost 30 years ago), which was used for the treatment of melanoma, kidney cancer, follicular lymphoma, and various types of leukemia [4].